PURE Bioscience Profit Margin

The latest profit margin for PURE is -91.04% as of April 2026. That compares with -147.65% in the prior-year period — up 38.3% year over year. That is below the sector sector average of 21.49%. Investors often review this figure alongside PURE Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, PURE's profit margin moved from -147.65% to -91.04% — a 38.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PURE Bioscience's valuation or profitability profile.

Against its sector companies, PURE currently prints -91.04% for profit margin, while the sector average sits near 21.49%. That is roughly 523.6% below the sector mean. Large gaps often invite a closer look at PURE Bioscience's growth, margins, and balance sheet.

Profit Margin shows how effectively PURE Bioscience converts resources into returns. At -91.04%, PURE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -147.65% in the prior-year period — up 38.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PURE's profit margin (-91.04%), review year-over-year change from -147.65%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.